Short term statin treatment in idiopathic dilated cardiomyopathy

Egyptian Heart Journal

Volumn 64, Issue 1, 2012, Pages 15-20

  Awwad, Omar ^a   El Zahwy, Sherif S ^a   Shawky, Ahmed ^a   Attia, Sameh ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Cardiomyopathy; CRP; Statins

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; PLACEBO; SPIRONOLACTONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PERFORMANCE; HUMAN; INFLAMMATION; MALE; SHORT COURSE THERAPY;

EID: 84879192039     PISSN: 11102608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2011.08.020     Document Type: Article

References (22)

1. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult Executive Summary. J Am Coll Cardiol 2001;101:38.
2. Givetz M., Colucci W., Braunwald E. Clinical aspects of heart failure; Pulmonary edema, High-output failure. Braunwald's Heart Disease 2005, 541-543. Elsevier Saunders. 7th edition. D. Zipes, P. Libby, R. Bonnow, E. Braunwald (Eds.).
3. Cohn J.N., Quyymi A.A., Hollenberg N.K., et al. Surrogate markers for Cardiovascular disease. Functional markers. Circulation 2004, 109:431-446.
4. Moens A.L., Goovearts I., Claeys M.J., et al. Flow-mediated vasodilation. A diagnostic instrument, or an experimental tool?. Chest 2005, 127:2254-2263.
5. Rector T.S., Cohn J.N. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992, 124:1017-1025.
6. Rector T.S., Francis G.S., Cohn J.N. Patients' self assessment of their congestive heart failure. Part 1 patient perceived dysfunction and its poor correlation with maximal exercise tests. Heart failure 1987, 192-196.
7. Anand I.S., Latini R., Florea V.G., et al. C- reactive protein in heart failure. Prognostic value and the effect of valsartan. Circulation 2005, 112:1428-1433.
8. Solway S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 2001, 119(1):256-270.
9. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
10. Watts G.F., O'Brien S.F., Silvester W., et al. Impaired endothelial dependant and independent dilation of forearm resistance in men with diet-treated non-insulin-dependant diabetes: role of dyslipidemia. Clin Sci Lond 1996, 91:567-573.
11. Naqvi T.Z. Comparison of myocardial tissue Doppler with transmitral flow Doppler in left ventricular hypertrophy. J Am Soc Echocardiogr 2001, 14(12):1153-1160.
12. O'Driscoll G., Green D., Taylor R.R., et al. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997, 95:1126-1131.
13. Strey C.H., Young J.M., Lainchbury J.H., et al. Short-term statin treatment improves endothelial function and neurohormonal imbalance in normo-cholesterolaemic patients with non-ischaemic heart failure. Heart 2006, 92:1603-1609.
14. Laufs U., Wassmann S., Schackmann S., et al. Beneficial effects of statins in patients with non ischemic heart failure. Z Kardiol 2004, 93:103-108.
15. Wojnicz R., Wilczek K., Nowalany-Kozielska E., et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006, 98(5):707.
16. Node K., Fujita M., Kitakaze M., et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003, 108:839-843.
17. Sola S., Mir M.Q., Rajagopalan S., et al. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail 2005, 11:607-612.
18. Tousoulis D., Antoniades C., Vassiliadou C., et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 2005, 7:1126-1132.
19. Horwich T.B., MacLellan W.R., Fonarow G.C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004, 43:642-648.
20. Bleske B.E., Nicklas J.M., Bard R.L., et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low density lipoprotein level. J Am Coll Cardiol 2006, 47:338-341.
21. Yamada T., Node K., Mine T., et al. Long-term effect of atorvastatin on neurohumoral activation, cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 2007, 153:6.
22. Liu M., Wang F., Wang Y., Jin R. Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation. Cardiovasc Drugs Ther 2009, 23(5):369-376.